test

Clinical Trials

Bladder Cancer

10
A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects with Metastatic Urothelial Cancer
Disease/Condition: Bladder
Principal Investigator: Daniel Petrylak
A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
Principal Investigator: Daniel Petrylak
A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Cervix Uteri | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Multiple Myeloma | Non-Hodgkin's Lymphoma | Other Female Genital | Other Male Genital | Pancreas | Prostate | Rectum | Soft Tissue | Stomach | Thyroid
Principal Investigator: Roy Herbst
A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer
Disease/Condition: Bladder
Principal Investigator: Daniel Petrylak

Kidney Cancer

Prostate Cancer

10
A Multinational, Phase III, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
A Randomized Open-label Phase IIa Study Evaluating Quantified Bone Scan Response Following Treatment With Radium-223 Dichloride Alone or in Combination With Abiraterone Acetate or Enzalutamide in Subjects With Castration-resistant Prostate Cancer Who Have Bone Metastases
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
A Three Arm Randomized Open-label Phase II Study of Radium-223 Dichloride 50 kBq/kg Versus 80 kBq/kg, and Versus 50 kBq/kg in an Extended Dosing Schedule in Subjects With Castration-resistant Prostate Cancer Metastatic to the Bone
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
Assessing the support care needs, quality of life and relationship satisfaction of men with prostate cancer and their spousal caregivers: a cross-culture comparison between Chinese and American couples.
Disease/Condition: Prostate
Principal Investigator: Dwain Fehon
Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men with Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy
Disease/Condition: Prostate
Principal Investigator: Daniel Petrylak
RTOG 0815: Randomized Trial With or Without Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer
Disease/Condition: Prostate | Prostate Cancer
Principal Investigator: Joseph Cardinale